Find uplifting stories about heroes, innovations, and solutions
5 results for "cytokinetics"
A breakthrough clinical trial offers the first successful treatment for patients with non-obstructive heart disease who've had zero approved therapies. The drug improved both quality of life and exercise capacity in people living with a challenging heart condition.
A pharmaceutical breakthrough just opened doors for patients with a heart condition that's never had an approved treatment. Cytokinetics' drug Myqorzo succeeded in treating non-obstructive hypertrophic cardiomyopathy, doubling the number of people who could benefit from this therapy.
After 27 years, biotech company Cytokinetics could win its second FDA approval in record time with a groundbreaking heart drug. The medication would be the first treatment specifically designed for a type of inherited heart disease that affects thousands of Americans.
A new treatment for an inherited heart condition just cleared a major hurdle that could help thousands more patients access life-changing care. Cytokinetics announced their drug Myqorzo significantly improved symptoms for people with a less severe form of heart disease.
A breakthrough medication could become the first FDA-approved treatment for a common inherited heart disease affecting hundreds of thousands of people. Patients who've lived with limiting symptoms finally have reason for hope.